25 completed, 3 terminated, 2 unknown, 1 withdrawn. 31 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 25, Terminated 3, Unknown 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Brimonidine Tartrate: new trials by email Literature Review of Brimonidine Tartrate trials Research Report on Brimonidine Tartrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness BTOS-HA, Lumify® - Ocular Redness | Phase 3 | Completed | Bausch & Lomb Incorporated | 578 | 2025-05-22 | 2026-05-28 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Brimonidine - Presbyopia, Refractive Error | Phase 3 | Completed | LENZ Therapeutics, Inc | 469 | 2022-12-19 | 2026-05-13 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025% - Seasonal Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 229 | 2022-11-18 | 2025-07-01 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness" Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%) - Ocular Redness | Phase 3 | Completed | Bausch & Lomb Incorporated | 380 | 2022-05-13 | 2024-08-26 |
| Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate - Presbyopia | Phase 3 | Completed | Visus Therapeutics | 182 | 2022-03-30 | 2024-10-15 |
| Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia BRIMOCHOL™ PF, Carbachol PF, Vehicle - Presbyopia | Phase 3 | Completed | Visus Therapeutics | 629 | 2022-03-15 | 2025-08-06 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease Brimonidine Tartrate, Placebos - Graft Versus Host Disease, Ocular Surface Disease | Phase 3 | Terminated | Ocugen | 59 | 2018-12-23 | 2022-07-06 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) Brimonidine Tartrate, Placebos - Dry Eye | Phase 3 | Completed | Ocugen | 252 | 2018-12-03 | 2022-07-18 |
| PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic - Primary Open-angle Glaucoma | Phase 3 | Terminated | Laboratorios Sophia S.A de C.V. | 51 | 2017-11-06 | 2025-03-06 |
| Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations Brimonidine 0.33% gel - Capillary Malformations | Phase 3 | Terminated | The Hospital for Sick Children | 6 | 2016-06-01 | 2019-04-16 |
| Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) PRO-122, Krytantek Ofteno® - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratorios Sophia S.A de C.V. | 60 | 2016-04-01 | 2019-12-09 |
| Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT) Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, Brinzolamide 10 mg/mL eye drops, suspension, Brimonidine 2 mg/mL eye drops, solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 493 | 2015-04-14 | 2018-07-02 |
| Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea Brimonidine, placebo - Rosacea | Phase 3 | Completed | Actavis Inc. | 462 | 2014-07-01 | 2020-01-14 |
| Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants Brimonidine Tartrate, Vehicle, Sodium Fluorescein - Hyperemia | Phase 3 | Completed | Bausch & Lomb Incorporated | 507 | 2014-02-22 | 2019-10-23 |
| Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness Brimonidine Tartrate, Vehicle, Sodium Fluorescein - Hyperemia | Phase 3 | Completed | Bausch & Lomb Incorporated | 60 | 2013-11-07 | 2019-10-23 |
| Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution - Glaucoma, Ocular Hypertension | Phase 3 | Withdrawn | Allergan | 2013-07-01 | 2013-07-18 | |
| Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy COLIRIOBCN070660, Placebo, Brimonidine - Diabetic Retinopathy | Phase 2 / Phase 3 | Completed | BCN Peptides | 450 | 2013-02-01 | 2016-01-12 |
| Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, Vehicle, Brinzolamide 1% ophthalmic suspension - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 1184 | 2011-05-01 | 2014-04-07 |
Showing 20 of 31. Sign in to see all of them.
Ocular Hypertension (13) · Glaucoma (8) · Glaucoma, Open-Angle (7) · Presbyopia (3) · Conjunctivitis, Allergic (2) · Hyperemia (2) · Capillary Malformations, Congenital, 1 (1) · Corneal Edema (1) · Diabetic Retinopathy (1) · Dry Eye Syndromes (1) · Eye Diseases (1) · Glaucoma, Angle-Closure (1) · Graft vs Host Disease (1) · Myopia (1) · Port-Wine Stain (1)
Allergan (7) · Bausch & Lomb Incorporated (7) · Alcon Research (5) · Laboratorios Sophia S.A de C.V. (2) · Ocugen (2) · Visus Therapeutics (2) · Actavis Inc. (1) · BCN Peptides (1) · LENZ Therapeutics, Inc (1) · Rabin Medical Center (1) · Singapore Eye Research Institute (1) · The Hospital for Sick Children (1)
United States (18) · Canada (1) · Colombia (1) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Mexico (1) · Portugal (1) · Singapore (1) · Spain (1) · United Kingdom (1)
Heleen DeCory (2) · James Teague, BS, Sr. Clinical Manager (2) · Anat Robinson, MD (1) · Daniel Donatello (1) · Elena Pope, MD (1) · James Teague, Sr. Clinical Manager (1) · Kris Gambelin, BS (1) · Leopoldo Baiza, MD (1) · Nageshwar R Thudi, Ph.D. (1) · Steve Burmaster, PhD (1) · Tin Aung, FRCOphth (1)
PMID 18534052, PMID 23579344, PMID 25429421, PMID 25430900, PMID 28663190, PMID 28785768, PMID 29461408, PMID 29680880, PMID 40711722, PMID 41737851